FDA OKs expanded use for PTC’s Emflaza

The FDA has approved the use of PTC Therapeutics’ (PTCT +3%) Emflaza (deflazacort) in Duchenne muscular dystrophy (DMD) patients as young as two years old.

The agency first approved the corticosteroid in February 2017 for DMD patients at least five years old.

https://seekingalpha.com/news/3469896-fda-oks-expanded-use-ptcs-emflaza-shares-3-percent